Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

time. Investors interested in listening to the live webcast should log on before the presentation begins to download any software required. The archive of the presentation will be available for several days following the event.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is awaiting authorization to begin the delivery of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical development pipeline.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... China,s startup business ... a wearable medical device that can continuously monitor the ... safety guidance for pregnant women. The device will debut ... which measures 4 centimeters in diameter, is as thin ... than an Apple earphone cord. The small and compact ...
(Date:9/3/2015)... Sept. 3, 2015  Four financial reasons to ... white paper released by Leaf Healthcare, Inc . ... Research & Quality (AHRQ), pressure ulcers cost ... annually . In addition to direct treatment related ... penalties, and negatively impact hospital performance metrics. On ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... of the "Investigation Report on China Tamsulosin ... Compared with other a1- adrenergic receptor ... selectivity and lower risk of urinary tract infections ... since its debut in 1993 in ...
Breaking Medicine Technology:Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3China Tamsulosin Market Investigation Report 2015 2
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse ... that may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and ... often caused by HPV infections, which have a high rate of success in treatment ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... its upcoming virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” ... Health, Express Scripts and Milliman, will discuss how plan sponsors are adopting bold, ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow ... and eCOA Congress in Lisbon, Portugal, September 22-24, 2015. The esteemed faculty ...
(Date:9/3/2015)... ... ... unavoidable result of incision or injury to the skin. Unsightly as it may be, a ... a scar is dependent on many factors – the size and depth of the wound ... invisibility on their own over a period of months,” says Dr. Jocelyn Lieb ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mum n Me is pleased ... product offers an extra-large size that gives maximum protection from sun exposure, wind, bugs, ... attachment straps that deliver non-slip assurance by keeping the cover securely in place. The ...
Breaking Medicine News(10 mins):Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Mum n Me Announces New Baby Car Seat Cover 2
... the scientists at the Glasgow University, English cider apples have ... stroke, heart// disease and cancer. ,Thus, a pint ... the doctor away!,The scientists plan to test cider’s effects by ... The volunteers will drink 500ml of cider in a controlled ...
... revealed that nearly 40 per cent of the respondents ... especially during the bygone three months. , ... shown that 81 per cent of households required medical ... waiting times were unwarranted. Many felt that emergency care ...
... most comprehensive examination of human genome with an aim to ... done by the scientists at the Molecular// Neurobiology Branch of ... Health. ,Identification of genes connected with substance abuse ... technology for the first time in this study. The December ...
... given to schoolgirls from the age of nine to protect ... to yesterday’s report. ,However Scots church leaders ... the "green light" to under-age sex. It is because of ... resisted vaccinating young girls as yet. ,Trials ...
... A British court has awarded a 63-year-old doctor of ... and flirting with women patients over a 13-year //period ... the India-born doctor who qualified in India, moved to ... in Grimsby since 1990. His one-man practice had 2,900 ...
... Saturday kick-started an HIV/AIDS control initiative to bring 1,000 ... ,State Governor S.S. Barnala called on varsity vice-chancellors ... onerous responsibility to chalk out plans for RRCs in ... said: "The youth today is fully aware of AIDS ...
Cached Medicine News:Health News:From genes to alcoholism 2Health News:From genes to alcoholism 3Health News:Controversial Vaccine Raises Fury of the Church 2Health News:Indian Doctor in Britain Jailed for Molesting Patients 2Health News:Anti-AIDS Plan for 1,000 Tamil Nadu Colleges 2
The control unit circulates temperature-controlled water through disposable gel pads applied directly to the patient's body....
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care....
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Nitinol Paired Helical Basket...
Medicine Products: